Journal profile · Clinical Neurology
Neurodegenerative Diseases
ISSN 1660-2854 · eISSN 1660-2862 · S. Karger AG · SWITZERLAND · Bimonthly · Founded 2004
Neurodegenerative Diseases: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.65; hybrid open access; median 138 days to acceptance (41 articles, last 24 months); community-reported acceptance: moderate; 40 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Neurodegenerative Diseases is published by S. Karger AG and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Alzheimer's disease research and treatments, Parkinson's Disease Mechanisms and Treatments and Amyotrophic Lateral Sclerosis Research, together about 35.6% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
'Neurodegenerative Diseases' is a bimonthly, multidisciplinary journal for the publication of advances in the understanding of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and related neurological and psychiatric disorders.
Source: LetPub
Research area (LetPub): Clinical Neurology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Alzheimer's disease research and treatmentsMedicine17.1%
- Parkinson's Disease Mechanisms and TreatmentsMedicine9.7%
- Amyotrophic Lateral Sclerosis ResearchMedicine8.9%
- Dementia and Cognitive Impairment ResearchMedicine7.2%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance6.1%
- Genetic Neurodegenerative DiseasesNeuroscience5.6%
- Human auditory perception and evaluationEngineering5.4%
- Neurological disorders and treatmentsMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.65LetPub ·
- CiteScore 2026-06
- 3.6LetPub ·
- SJR 2026-06
- 0.51LetPub ·
- SNIP 2026-06
- 0.65LetPub ·
- h-index
- 52LetPub ·
- h-index
- 81OpenAlex ·
- i10-index
- 700OpenAlex ·
- 2-year mean citedness
- 1.54OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 52%LetPub ·
Volume
- Articles per year
- 24LetPub ·
Articles by year OpenAlex count · 1,291 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 25 | 14 | 1 |
| 2025 | 40 | 39 | 59 |
| 2024 | 37 | 14 | 97 |
| 2023 | 10 | 3 | 31 |
| 2022 | 23 | 8 | 165 |
| 2021 | 23 | 6 | 214 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
138 daysMedian, submission to acceptance · P25–P75 97 days – 183 days
- Acceptance to online
- median 10 days (41 articles)
- Submission to online
- median 143 days
- Sample
- 41 articles with submission and acceptance dates (50 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- S. Karger AG
- Country or region
- SWITZERLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2004
- ISSN
- 1660-2854
- Electronic ISSN
- 1660-2862
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Neurodegenerative Diseases
What CAS zone is Neurodegenerative Diseases in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neurodegenerative Diseases is in Zone 4 of Medicine, and in Zone 4 of the minor category Clinical Neurology / Neurosciences. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neurodegenerative Diseases?
The latest impact factor listed by LetPub is 2.65; CiteScore 3.6, h-index 81.
How long does peer review take at Neurodegenerative Diseases?
Based on the dates recorded on 41 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 138 days (interquartile range 97–183 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Neurodegenerative Diseases?
According to LetPub and DOAJ records, Neurodegenerative Diseases is indexed in SCIE and Scopus.
Is Neurodegenerative Diseases open access, and what is the APC?
Neurodegenerative Diseases is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .